- Report
- February 2024
- 70 Pages
Iran
From €4228EUR$4,750USD£3,659GBP
- Report
- February 2024
- 70 Pages
Brazil
From €4228EUR$4,750USD£3,659GBP
- Report
- February 2024
- 70 Pages
Russia
From €4228EUR$4,750USD£3,659GBP
- Report
- February 2024
- 70 Pages
Australia
From €4228EUR$4,750USD£3,659GBP
- Report
- February 2024
- 70 Pages
China
From €4228EUR$4,750USD£3,659GBP
- Report
- February 2024
- 70 Pages
Japan
From €4228EUR$4,750USD£3,659GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4228EUR$4,750USD£3,659GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4228EUR$4,750USD£3,659GBP
- Report
- October 2022
- 70 Pages
Africa
From €4228EUR$4,750USD£3,659GBP
- Report
- August 2020
- 150 Pages
Global
From €3783EUR$4,250USD£3,274GBP
- Report
- February 2024
- 95 Pages
Global
From €3500EUR$4,213USD£3,135GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,213USD£3,135GBP
- Report
- July 2025
- 50 Pages
Global
From €2359EUR$2,650USD£2,041GBP

Alogliptin is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released by the pancreas after meals. Alogliptin is typically used in combination with other diabetes medications, such as metformin, to help control blood sugar levels. It is also used to reduce the risk of cardiovascular events, such as heart attack and stroke, in people with type 2 diabetes.
Alogliptin is part of a larger class of drugs used to treat endocrine and metabolic disorders. These drugs are used to treat conditions such as diabetes, obesity, and thyroid disorders. They work by regulating hormones and other substances in the body that affect metabolism and energy production.
Some companies in the alogliptin market include Takeda Pharmaceuticals, Merck, and Eli Lilly. Show Less Read more